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Background: Heterogeneous by the underlying pathobiology and clinical presentation,
childhood onset dystonia is most frequently progressive, with related disability and limi-
tations in functions of daily living. Consequently, there is an obvious need for efficient
symptomatic therapies.
Methods and Results: Following lesional surgery to basal ganglia (BG) and thalamus, deep
brain stimulation (DBS) is a more conservative and adjustable intervention to and validated
for internal segment of the globus pallidus (GPi), highly efficient in treating isolated “pri-
mary” dystonia and associated symptoms such as subcortical myoclonus. The role of DBS
in acquired, neurometabolic and degenerative disorders with dystonia deserves further
exploration to confirm as an efficient and lasting therapy. However, the pathobiological
background with distribution of the sequellae over the central nervous system and related
clinical features, will limit DBS efficacy in these conditions. Cumulative arguments propose
DBS in severe life threatening dystonic conditions called status dystonicus as first line
therapy, irrespective of the underlying cause.
There are no currently available validated selection criteria for DBS in pediatric dys-
tonia. Concurrent targets such as subthalamic nucleus (STN) and several motor nuclei of
the thalamus are under exploration and only little information is available in children. DBS
programming in paediatric population was adopted from experience in adults. The choice
of neuromodulatory DBS parameters could influence not only the initial therapeutic
outcome of dystonic symptoms but also its maintenance over time and potentially the
occurrence of DBS related side effects.eurochirurgie, Centre Hospitalier Universitaire Montpellier, Universite Montpellier, 80,
edex 5, France. Fax: þ33467337464.
(L. Cif).
y Elsevier Ltd on behalf of European Paediatric Neurology Society. This is an open access
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e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 1 ( 2 0 1 7 ) 1 0 9e1 1 7110Conclusion: DBS allows efficient symptomatic treatment of severe dystonia in children and
advancespathophysiologicalknowledgeabout localanddistributedabnormalneuralactivity
over the motor cortical-subcortical networks in dystonia and other movement disorders.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology
Society. This is an open access article under the CC BY-NC-ND license (http://
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Childhood neurology accounts for awide spectrumof diseases
that encompasses, at different stages of their progression,
various movement disorders, impacting development and
functional capacities. Scientific progresses and technological
developments over the last decades improved symptomatic
treatment. However, their application in pediatric movement
disorders is still limited and efficacy variable when addressing
the type of movement disorder, the associated symptoms and
the lack of guidance by the underlying pathobiology.
In the spectrum of pediatric movement disorders, dystonia
represents the most frequent, persistent, potentially most
severe and most challenging movement disorder.
According to the recently revised classification, which does
not address specifically pediatric aspects, dystonia is classi-
fied along two axes: clinical characteristics, including age of
onset, body distribution, temporal pattern and associated
features; and etiology, which includes nervous system pa-
thology and inheritance.1 In children, dystonia has many
diverse etiologies,2 the underlying pathobiology as well as
related phenotypes are heterogeneous and complex; age and
symptom distribution at onset may sometime inform about
the underlying causes. A recent study conducted in a pediatric
population reported that dystonia severity frequentlyworsens
in primary, secondary and heredodegenerative aetiologies,
remaining at best static in one third of cases, meanwhile
spontaneous improvement will be an exceptional scenario.3
Childhood onset dystonia often becomes generalized,
involving progressively an increasing number of body parts
and impair the evolving functional capacities at various
developmental stages. Furthermore, it is combined withassociated neurological and systemic signs and symptoms,
rendering assessment challenging and prognosis risky with
significant, life-long reduction of activity and participation.42. Assessment of dystonia
Dystonia assessment is higly challenging since there is no
available «perfect» dystonia rating scale with demonstrated
validity, reliability, and utility across multiple forms of dys-
tonia, combined dystonia and taking into account different
ages in pediatrics. Several rating scales assessing dystonia
have been developed such as the Barry-Albright Dystonia
Scale (BADS)5 and the most frequently used dystonia rating
scale is the Burke-Fahn-Marsden Dystonia Rating Scale
(BFMDRS),6 designed for isolated generalized dystonia. How-
ever, this scale was not validated in young children with
dystonia, where the disability section score could be impacted
by the developmental stage as much as by dystonia. Further-
more, in combined dystonia, disability scores can be further
altered by associated symptoms.
The long time period for monitoring the disease progres-
sion and efficacy of treatment in patients with dystonia pre-
vents the adequate use of a single assessment tool equally
suitable in young children, teenagers and adults over the
longitudinal follow-up. Assessment must take into account,
for every point in time, the sum of the effects of the thera-
peutics used and of the potential disease progression,
compared with the previous assesments. A stable or worse
motor score compared to baseline condition does not neces-
sarily mean that the therapeutical approach used was unef-
fective, but could also mean that the underlying disease
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dystonia. Interpretation of the results reported in the litera-
ture must take into account these considerations and related
biases.
Most children with dystonia have other movement disor-
ders, and hence, a valid and reliable method to disentangle
dystonia from other movement disorders in children is
mandatory.2,73. Limited therapeutical options for treating
childhood dystonia
Several treatment options of childhood dystonia are available
including oral pharmaceutical agents and botulinum toxin
injections. However, high-quality evidence on dosing
different medications in children is lacking. Pharmacological
treatment is used most frequently “off-label” for pediatric
movement disorders, including dystonia. Most dystonias are
treated by trying sequentially a handful of medications
starting with those with the best risk/benefit profile.8 The
most commonly used oralmedications for treating dystonia in
children are trihexyphenidyl, baclofen, and levodopa,
together with benzodiazepines, as confirmed by a recent
publication.9 The antidopaminergics were also found to be
effective. Other agents have shown usefulness in controlling
dystonia such as carbamazepine10 and gabapentin with re-
ported efficacy in a recent retrospective study for improving
dystonia severity, quality of life and pain in children with
dystonia.11 Introduction and titration of pharmaceuticals as
well as discontinuation are challenging in children with dys-
tonia. Several drugs reported as efficient for treating dystonia
were also incriminated as triggering factors for severe dys-
tonic symptoms and status dystonicus.12 Botulinum toxin
injections have relatively limited impact because of general-
ized symptoms. For all these reasons, therapeutical manage-
ment of children with dystonia is highly challenging faced
with potentially progressive disorders.4. Lesional surgery versus deep brain
stimulation
Since the early sixties the efficacy of lesional surgery in dys-
tonia has been reported following chemopallidectomy13,14
with a renewed interest for pallidotomy with the occurrence
of side effects related to levodopa therapy in Parkinson's dis-
ease.15 Limited, uncontrolled series reported that bilateral
pallidotomy would be similar to GPi DBS in effectiveness and
safety for dystonia. Pallidotomy remains a viable alternative
in situations where DBS is not available or not feasible16 and
should be reconsidered when the risk of complications of DBS
might be particularly high, or when patients/carers decline
the insertion of an implanted device.17 In a recent case series
of four children with dystonia, pallidotomy to the mid portion
of the GPi was followed by improvement of severe dystonic
state with longest benefit reported of 21 months.18 An 18-
month-old child, the youngest reported, underwent pallidot-
omy for disabling dystonia related to glutaric aciduria type 1
with significant initial improvement.19 However, very little isknown about the long term outcome of pallidotomy in these
indications. The exact role of lesional surgery for treating
dystonia in pediatric populations is to be further defined, since
the advent of technological progress and development of im-
aging techniques allow a better location andmonitoring of the
lesions.
DBS initially proposed for the treatment of essential tremor
and Parkinson's disease in adults.20,21 In 1996, a child with
severe life threatening dystonic condition was offered DBS
surgery to the internal globus pallidus22 with lasting efficacy
at 20 years (personal experience). Since that time, increasing
number of children benefited from therapy. DBS is a symp-
tomatic therapy improving a spectrum of symptoms, from
moderate to highly impairing muscle spasms or involuntary
movements, abnormal postures and associated pain, respi-
ratory distress or swallowing difficulties as well as additional
movement disorders like tremor, chorea or myoclonic jerks.
While the application of DBS in adults continues to expand,
pediatric indications for DBS have been more limited.23
Although there is now level A evidence that pallidal DBS is
an effective treatment of patients with isolated generalized,
segmental and cervical dystonia in adults, prospective,
controlled studies reporting DBS efficiency in the treatment of
pediatric isolated and acquired dystonia are not available.
Well documented retrospective studies in pediatric dystonia
are of interest since they can add valuable information to the
currently limited available experience.245. Selection criteria and indications for DBS
in pediatric dystonia
DBS is used to treat dystonia in young children, with results
ranging from dramatic to modest.25e27 Validated selection
criteria for DBS procedures such as response to medication in
Parkinson's disease and quantified severity criteria are lacking
in pediatric dystonia.24 Disability not influenced by medical
treatment and reduction in quality of life (QoL) were proposed
as the main factors guiding the decision to consider DBS, in-
dependent from age.17 Phasic component of dystonia, short
disease duration, absence of skeletal deformities, DYT1 gene
mutations in isolated dystonia and no associated weakness
and spasticity in acquired forms were all regularly reported as
good prognosis.28e30
Isolated generalized dystonia in children benefit from GPi
DBS, with initial clinical outcome reported as slightly superior
in children than in adults,28 thus, possibly related to the
shorter disease duration in the childhood dystonia groups.31
DBS outcome is reported superior in DYT1 dystonia related
to mutation in TOR1A gene compared to DYT6 dystonia
related to THAP1 gene mutations, however very little data is
available in children; anecdotal thalamic DBS has been re-
ported as a more successful DBS alternative in DYT6 dysto-
nia.32 Similar results to that obtained in DYT1 dystonia are
reported in myoclonus-dystonia related to SGCE gene muta-
tions in both, children and adults.33,34
In acquired and degenerative dystonia, response to DBS is
highly variable in relation with the associated symptoms
(spasticity and weakness, cerebellar symptoms) and impaired
motor network.35 However, subgroups of patients from the
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 1 ( 2 0 1 7 ) 1 0 9e1 1 7112vast group of acquired and degenerative dystonias deserve
further attention since it has been reported that they could
benefit from DBS.
In dyskinetic cerebral palsy (DCP), themost common cause
of dystonia in childhood30,36 mean improvements of 37.8% on
the M-BFMDRS section in children under sixteen have been
reported,36 comparable to other series in pediatric DCP37 and
with data in adults with DCP.38 However, these results are
superior to outcomes reported by the only controlled DBS trial
in adults with DCP39 and ameta-analysis on DBS in DCP.40 The
difference in the DBS outcome may be related to differences
between populations (extent of brain insult and sequellae,
functional reorganization in the motor network, motor
phenotype, age at DBS administration), assessment modality
or therapy characteristics (site of DBS electrode and DBS set-
tings), sample sizes but also the difficulties in capturing subtle
clinical changes while using the available tools.38 From per-
sonal experience in DBS for DCP, we can report higher benefits
in a subgroup of patients with documented hypoxic ischemic
encephalopathy (HIE) at birth and no other identified cause of
dystonia, who exhibited late onset dystonia and dyskinesia,
compared with the subgroup who exhibited motor symptoms
early, within the first year of life, thus, potentially related to a
less severe initial involvement and reorganization of the
motor network following perinatal brain insult. Due to the
limitation of systematic data on DBS in CP patients, there are
many unanswered questions. Selection of suitable patients
and counselling of families is often extremely difficult.41
From the heterogeneous and expanding group of neuro-
degeneration with brain iron accumulation (NBIA), DBS is
proposed in pantothenate kinase associated neuro-
degeneration (PKAN), related to mutations in PANK2 gene,
since it is frequently associated with severe, generalized
forms of dystonia. Positive outcome for GPi DBS was reported
by Castelnau et al. in a group of six patients with PKAN related
dystonia, three of them of pediatric age at DBS administra-
tion,42 confirmed by a multicenter retrospective study on 23
subjects (age at operation 23 years).43 Of interest, five out of
the six patients from the study by Castelnau and colleagues
survive with a maintained clinical and functional benefit ten
years after the initial report in this highly disabling progres-
sive disorder (personal experience of the author). Further-
more, observations of improved performance on cognitive
tests after DBS together with reports of improved school
attendance, participation in classroom activities, and educa-
tional performance in children and young people with PKAN
following DBS suggest that apparent cognitive impairments
may reflect difficulties in accessing cognition owing to
severity of dystonia, thus the intellectual decline previously
associated with PKAN may have been overestimated. This
information should further encourage earlier administration
of DBS in PANK2 gene mutation-related dystonia.44 Multi-
centre, controlled prospective studies are necessary to get
large numbers of cases of this heterogeneous condition to
better predict the outcome from surgery.43
The effect of DBS in other acquired (prematurity, kern
icterus),25,35 neurodevelopmental and degenerative dystonias
(Lesch-Nyhan syndrome, Mohr-Tranebjaerg syndrome, glu-
taric aciduria) in children has been only anectodatly reported,
with highly variable results.45e47 Children with secondarydystonia should continue to be offered DBS, but goals and
expectations must reflect a less dramatic improvement than
in primary dystonia.35
Whether DBS is a symptomatic therapy, only limited in-
formation is available for DBS specific effect on the variety of
symptoms present in children with dystonia (phasic versus
tonic component, dystonic tremor), their topographic distri-
bution (proximal versus distal appendicular, axial, cervical,
cranial) over distinct body parts, effect on speech impairment,
swallowing, severity of the symptoms and pain. It has been
reported that DBS, early after initiation, alleviates painful
spasms, independently the underlying dystonia causes.22,31,42
Dysphagia can sometimes be improved following GPi DBS
with recovery of oral feeding in children with dystonia who
had percutaneous enteral gastrostomy feeding.22,47 Dysathria,
tongue protrusion dystonia and oro-mandibular dystonia
improvement is less reported37,42 than improvement of limb
and axial48 dystonia, however these symptoms frequently
occur mainly in children with acquired and degenerative
forms of dystonia. Gait and posture recovery represent
reasonable objectives in isolated primary dystonias22,28,42,48
but will be most often highly challenging objectives in ac-
quired dystonias.31 Related to specific symptoms, isolated
tonic component involving the limbs, fixed dystonic pos-
tures,22,48 as well as decreased muscle tone will negatively
impact DBS outcome. Dystonic tremor, motor tics and
myoclonic jerks can frequently be improved by DBS to GPi.
Children with both isolated and acquired dystonia may
experience acute deterioration of their condition, termed
‘status dystonicus’ that require prompt medical or surgical
care. Several case reports of acquired, degenerative as well as
isolated dystonia, including the first child treated with GPi
DBS for dystonia,22 presented with this condition at DBS
administration.42,49 DBS has been reported more efficient
compared to the best medical management in reverting these
severe conditions.49 Prompt identification may potentially
facilitate intervention and prevent progression.506. DBS settings in pediatric dystonia
Onset of DBS programming can be started immediately after
the surgical procedure and after validation of the right position
of DBS leads and absence of surgery related complications, or
several weeks after the surgery, in order to overcome potential
improvement related to the lead insertion lesional effect.
Evidence-based recommendations and guidelines are not
available for therapy initiation and adjustment for the treat-
ment of dystonia in children and settings are similar to those
used in adult dystonia. Systematic evaluations of varying DBS
settings have not been conducted in pediatric dystonia,30
however, a systematic approach to optimize stimulation pa-
rameters is highly recommended.51 High frequency stimula-
tion (frequency >100 Hz) is most frequently reported as
efficient, however lower frequencies (60 Hz) seem equally
useful in improving dystonic features.30,36 Monopolar or bipo-
lar stimulation, with various combinations of amplitudes,
narrower pulse widths (PWs (60e90 microsec) or wider PWs
(210e450 microsec) may provide similar efficacy in treating
dystonia28,35. DBS to distinct nuclei (GPi andmotor nuclei of the
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combined dystonia34 and suggested tomodulate alteredmotor
networks in acquired dystonia.52 Subthalamic nucleus (STN)
DBS has been occasionally proposedwhenGPiwas structurally
impaired by the pathological process and more recently to
prevent side effects related to GPi DBS, namely bradykinetic
features. However, one should be cautious since the long-term
therapeutic and potential side effects in these concurrent tar-
gets are not sufficiently explored.7. Long term DBS management in pediatric
dystonia
When compared with indications in adult movement disor-
ders including dystonia, DBS for treating pediatric dystonia
and associated movement disorders is faced with constant
challenges related to interference with developing brain and
normal functions, different motor developmental stages, to
the potential progression of the disorders over time (frequent
in pediatric movement disorders), and the need to provide a
lasting therapy. Response to DBS is highly variable and
frequently symptoms targeted by DBS in pediatric dystonia
remain progressive and fluctuating, also during followup after
DBS therapy. While lasting DBS efficiency has been reported
up to ten years in pediatric dystonia with overall maintenance
of the clinical improvement, worsening of dystonic symptoms
and tolerance to the therapy also occurred, necessitating
staged or rescue DBS interventions. Multiple electrodes to the
GPi have already been proposed to overcome incomplete
initial therapeutic effect, symptom progression under DBS or
as rescue therapy.27,53 Patients, families and caregivers should
be adequately informed at the time of initial DBS indication.8. DBS mechanisms of action, relationship
with dystonia pathophysiology and further
technological developments
Whilst previous models indicated basal ganglia (BG) as key
structures in the pathophysiology of dystonia, it is becoming
clear that many other brain regions can contribute including
cerebral cortex, cerebellum, thalamus, brainstem and spinal
cord. The challenge is to determine whether the alterations
across different nodes (spinal cord, somatosensory, BG, cere-
bellum, cortical) are causative, compensatory or epiphenom-
enal. Dystonia may result either from a single node
dysfunction, from involvement of multiple nodes or from
aberrant communication between the nodes as documented
by neurophysiology and imaging studies.54 Current imaging
approaches including whole-brain or region-specific studies
of structural or diffusion changes, functional imaging using
fMRI or positron emission tomography (PET), and metabolic
imaging using fluorodeoxyglucose PET provided evidence that
primary dystonia can be viewed as a circuit disorder, involving
the basal ganglia-thalamo-cortical and cerebello-thalamo-
cortical pathways.55 Three general abnormalities underly
dystonia physiological substrate: loss of inhibition, abnormal
sensorimotor integration and abnormal, excessive plasticity.
The network model in dystonia with alterations in multiplenodes could explain and reconcile these distinct proposed
abnormalities. Motor and sensory cortex in primary dystonia
exhibits an exaggerated responsiveness to transcranial mag-
netic stimulation (TMS) conditioning protocols. This abnormal
plasticity is not confined to the neural circuits affected by
dystonia but generalized across the entire sensorimotor sys-
tem representing an endophenotypic trait of dystonia.56
However, whether common pathophysiological features of
dystonia, including enhanced responsiveness of the motor
cortex to plasticity induction are shared by different types of
dystonia, differences in excitability of the corticocortical
axons and intracortical inhibition in myoclonus-dystonia
compared with isolated forms of dystonia have been docu-
mented.57 Furthermore, recent work proposed that not only
loss of inhibition can be documented in dystonia but also
enhanced inhibition, distant from affected body part which
could correspond to underlying compensatory network and
potentially represent in the future novel avenue for thera-
peutic targeting.58
Recordings of BG activity and firing during lesional surgery
and DBS procedures provide insight into the pathophysiolog-
ical basis of different types of dystonia. Related to BG neuronal
discharge in dystonia, it has been reported that Globus pal-
lidus pars externa (GPe) and GPi neurons display similar
discharge rates and patterns and that no difference has been
identified between the GPe and GPi neurons in patients whose
dystonia could be improved by posteroventral pallidotomy
(PVP) and those who did not benefit from PVP. Furthermore,
no significant differences in patients with dystonia of
different causes were discernible.59 Conversly, a recent pub-
lication in DBS treated dystonia patients reported differences
in firing rates and patterns related to aetiology and phenotype,
with higher firing frequency in the NBIA group than in the
primary and secondary static dystonia groups. Related to the
pattern of discharge, more regular firing cells were recorded
for the NBIA groups and, those with fixed dystonic versus
phasic dystonic components; furthermore, firing frequency
and response to DBS were correlated.60 Although these find-
ings need further documentation and confirmation, it would
be of interest, beyond the support for targeting, based on the
distinct neural firing patterns in various forms of dystonia, to
identify adjusted neuromodulatory therapeutics and DBS
prognostic criteria. Excessive oscillatory activity between 3
and 10 Hz in the local field potentials (LFP) of the pallidum in
patients with primary dystonia has been documented,61 the
magnitude of the pallidal oscillatory activity being correlated
with involuntary dystonic muscle activity.62 This abnormal
oscillatory activity could be the substrate of aberrant synaptic
plasticity within the cortical-BG network, since increase of
neuronal oscillations may facilitate cortical plasticity.63
Pallido-cerebellar oscillatory connectivity and its association
with dystonic symptoms provides further confirmation of
cerebellar involvement in dystonia.64
DBS mechanisms of action are not fully understood. DBS
suppresses or overrides pathological oscillatory network ac-
tivity within the cortex-basal ganglia loop.65,66 There are now
arguments in favour of alteration of the main physiological
parameters underlying dystonia pathophysiology: decreased
inhibition and excessive plasticity. The influence of GPi DBS
onmotor cortex excitability has been studied at early and later
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physiological changes is not identical, intracortical inhibition
normalizing in parallel with the clinical changes, meanwhile
excessive plasticity drop fast, after DBS initiation, to
normalize at the time of the clinical steady state.67 Short-term
effects related to switching off and on the IPG 3 months after
electrode implantation on motor cortical excitatory and
inhibitory neuron examined with transcranial magnetic
stimulation (TMS) led to a decrease of motor cortex excit-
ability, and reduced the size of contralateral responses,
reversible within minutes after switching on GPi stimulation,
associated with mild changes of dystonia. By contrast, mea-
sures of intracortical inhibition were not altered by switching
off GPi stimulation.68 Interestingly, at later stages of DBS
administration in dystonia, overall, there was no change in
average physiological or clinical status when DBS was turned
off for 2 days, suggesting that DBS had produced long-term
neural reorganization in the motor system.69 In the long
term, the LTP-like plasticity will be further altered by DBS to
reach a level, after years of continuous DBS, inferior to that
measured in healthy controls (at group level).69 DBS-induced
alterations of plasticity seem to be correlated with the level
of DBS administered: higher levels of DBS, more profound
LTP-like plasticity decrease, ressembling measures in naı¨ve
PD patients. The amount of residual plasticity under DBS is
correlated with the degree of clinical worsening at DBS
discontinuation.70
Importantly, it has been reported that GPi DBS may induce
bradykinetic symptoms or parkinsonism in adult patients
who receive effective stimulation for dystonia.71 but also in
pediatric dystonia. Consequently, alternative targets as STN
DBS are proposed, however, there are scant comparative data
on the efficacy of STN in dystonia, especially in the long term.
DBS disease-modifying effect has been questioned since
several publications reported clinical stability upon DBS
discontinuation after years of continuous DBS administration
in dystonia.70,72 However, physiological measures indicate
DBS is a life-long therapy since physiological changes induced
by prolonged, continuous DBS would be reversible at DBS
discontinuation.73
Abnormal plasticity seems to be a primary intrinsic ab-
normality, which can predispose to the development of dys-
tonic movements. Of crucial importance for DBS is whether
intervention in a single node can be sufficient to impact
abnormally synchronised activity within the motor network
andrevert abnormalplasticity in thevarious formsofdystonia.
On the other hand, neuromodulation could impact not only
abnormal excessive plasticity demonstrated to be one of the
key underlying physiological hallmarks of dystonia but also,
normal plasticity. Overcorrection of excessive plasticity or
impact on normal plasticity could drive new symptoms,
clinical worsening or tolerance to DBS in dystonia.
The way the therapy is administered in a given target is
critical. Careful management of the therapy with the lowest
efficient doses should be proposed since the pathological but
also physiological underlying background could be altered by
DBS.
Technological developments provide devices that allow
simultaneous LFP recordings and immediate effect of DBS on
pallidal LFPs in patients with different types of dystonia andmonopolar high frequency stimulation (HFS).74 Recently it has
been documented that HFS suppresses low frequency activity
contemporary with the clinical reduction in phasic compo-
nent of dystonia.75 Pulse generators with longer battery
longevity, segmental electrode designs allowing a current
steering, and the possibility to deliver “on-demand” stimula-
tion based on closed-loop concepts76 represent prospects for
the future management with advanced treatment methods of
pediatric movement disorders.9. Conclusion
In conclusion, DBS is an efficient therapy in pediatric dystonia,
the response to DBS therapy varies according especially to
etiology and phenotype, underlying physiology but also inside
the same patient group. Treating dystonia in children with
DBS requires a multidisciplinary team to select candidates,
identify reasonable target symptoms, perform the procedure,
cope with complications related to therapy and devices,
optimize DBS administration, support the patients and fam-
ilies over the changing life. Treating dystonia earlier with the
lower efficient doses in pediatric populations seems to have a
better impact on the long term outcome. While putting
together the cost of complementary therapeutical approaches
in childhood dystonia, DBS can represent a reasonable ther-
apeutical approach when candidates are well selected and
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